UPSTREAM BIO, INC. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
UPSTREAM BIO, INC. (UPB) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of -$3.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-11
- UPSTREAM BIO, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$4.29M, a 221.67% decline year-over-year.
- UPSTREAM BIO, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $1.23M.
- UPSTREAM BIO, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $2.82M, a 60.74% increase year-over-year.
- UPSTREAM BIO, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$481.00K, a 285.71% decline year-over-year.
- UPSTREAM BIO, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $4.01M, a 165.48% increase from fiscal 2024.
- UPSTREAM BIO, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was $1.51M, a 258.29% increase from fiscal 2023.
- UPSTREAM BIO, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was $422.00K.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$3.06M 10-Q · filed 2026-08-11 | -$239.00K derived: sum of 3 quarters · filed 2026-08-11 | -$720.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.23M 10-Q · filed 2026-05-13 | $4.05M derived: sum of 2 quarters · filed 2026-05-13 | $3.57M derived: sum of 3 quarters · filed 2026-05-13 | $7.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.34M derived: sum of 2 quarters · filed 2026-03-26 | $5.87M derived: sum of 3 quarters · filed 2026-08-11 | $4.01M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$481.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.04M derived: sum of 2 quarters · filed 2026-08-11 | $1.19M 10-Q · filed 2025-11-05 | $2.95M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $3.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.67M 10-Q · filed 2026-08-11 | $3.43M derived: sum of 3 quarters · filed 2026-08-11 | $3.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$1.85M 10-Q · filed 2026-05-13 | -$96.00K derived: sum of 2 quarters · filed 2026-05-13 | $163.00K derived: sum of 3 quarters · filed 2026-05-13 | $545.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.01M derived: sum of 2 quarters · filed 2026-03-26 | $2.40M derived: sum of 3 quarters · filed 2026-03-26 | $1.51M 10-K · filed 2026-03-26 |
| 2024-09-30 | $259.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $641.00K derived: sum of 2 quarters · filed 2025-11-05 | -$243.00K 10-Q · filed 2025-11-05 | $396.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $382.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$502.00K 10-Q · filed 2025-08-06 | $137.00K derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | -$884.00K 10-Q · filed 2025-05-06 | -$245.00K derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | $639.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $422.00K 10-K · filed 2025-03-12 | ||
| 2023-09-30 | -$217.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |